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Abstract Recent experimental evidence suggests that poly-
ethylene glycol (PEG) is a highly effective chemopreventive
agent against colon cancer; however, the mechanism(s) remain
largely unexplored. To further elucidate this issue, we evaluated
the effect of PEG on two human colon cancer cell lines. PEG
treatment resulted in a dose- and time-dependent reduction in
cell number without alteration in markers of cell proliferation.
However, there was a dramatic and specific, concentration-
dependent induction of apoptosis, with 50 mM PEG rendering
approximately half the cells apoptotic. This corresponded with a
17-fold induction in the expression of the pro-apoptotic protein,
prostate apoptosis response-4. Our data suggest that induction of
apoptosis may be responsible, at least in part, for the ability of
PEG to prevent experimental colon cancer. ß 2001 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Experimental and clinical studies have demonstrated that a
variety of structurally unrelated agents protect against colon
cancer; however, limited e⁄cacy and/or potential toxicity of
most of these agents have impeded their clinical implementa-
tion [1]. Recent data from experimental models of colon can-
cer suggests that polyethylene glycol (PEG) may be the most
e¡ective chemopreventive agent studied to date, surpassing
even the non-steroidal anti-in£ammatory drugs (NSAIDs)
[2^6]. Furthermore, oral PEG solutions have been used safely
in humans to treat chronic constipation [7]. While the mech-
anism of action of PEG has not been explored, chemopreven-
tive agents against colon cancer typically induce epithelial ap-
optosis and/or inhibit cellular proliferation in colonic
epithelial cells [1]. It was our aim, therefore, to investigate
the e¡ect of PEG on apoptosis and cell proliferation in human
colon cancer cell lines. In order to investigate potential mo-
lecular mechanisms involved, we also evaluated the expression
of prostate apoptosis response (Par)-4, a protein recently im-
plicated in NSAID-induced apoptosis in colon cancer cells [8].
2. Materials and methods
2.1. Cell culture
HT-29 and CaCo-2 cells (American Type Tissue Culture, Rockville,
MD, USA) were grown in Dulbecco’s modi¢ed Eagle’s medium and
minimal essential medium, respectively, with 10% fetal calf serum (all
from Gibco Lifesciences, Grand Island, NY, USA). Cells were treated
with PEG (molecular weight 800), sterile sorbitol or sodium chloride
(Sigma, St. Louis, MO, USA).
2.2. Cell viability assay
Cell viability was assessed by measurement of the ability to metab-
olize 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) performed according to standard protocols [9]. Brie£y, cells
were grown in 96 well plates, washed and then incubated with MTT
for 4 h at 37‡C. Production of the tetrazolium salt was measured
spectroscopically at absorbance of 560 nm (Titertek Microskan,
Flow Laboratories, McLean, VA, USA).
2.3. Apoptosis assays
Apoptosis was quantitated using two distinct assays that we have
previously described [10]. Our primary method was through determi-
nation of the fraction of cells recognized by the M30 CYTODEATH
antibody (Boehringer-Mannheim, Indianapolis, IN, USA) using £ow
cytometry. This antibody detects a neo-epitope generated by caspase 3
degradation of cytokeratin 18 and, thus, is speci¢c for an early event
in apoptosis [11]. We con¢rmed this by evaluating the subdiploid
fraction of propidium iodide-treated cells also by £ow cytometry.
This method evaluates DNA degradation and, hence, is a later event
in apoptosis. We utilized the FACScalibur (Becton-Dickinson, San
Jose, CA, USA) £ow cytometer for these studies and CellQuest Soft-
ware (Becton-Dickinson, San Jose, CA, USA) for DNA content anal-
ysis while Mod¢t LT (Verity Software House, Chula Vista, CA, USA)
was used for M30 analysis.
2.4. Western blot analysis
Western blot analysis was performed as previously described [12].
Brie£y, cellular lysates (50 Wg protein) were subjected to SDS^PAGE,
transferred to polyvinylidene £uoride membranes, blocked with 5%
non-fat milk, and probed with polyclonal antibody to Par-4 and pro-
liferating cell nuclear antigen (PCNA) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Xerograms were developed with enhanced
chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ,
USA) and quantitated with laser densitometry. Equal protein loading
was con¢rmed by India ink staining of membranes and L-actin ex-
pression (Sigma, St. Louis, MO, USA).
3. Results
Incubation of the HT-29 and CaCo-2 colon cancer cells
with PEG did not result in immediate toxicity, as indicated
by trypan blue exclusion (data not shown). However, a dose-
dependent reduction in cell number was evident at all time
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points assessed (Fig. 1A). There was also a duration-depen-
dent e¡ect detectable at the higher PEG concentrations. Data
from the MTT assay were con¢rmed by manual cell counts
(data not shown). In order to exclude the possibility of a non-
speci¢c e¡ect from the PEG, we utilized both sorbitol and
sodium chloride as osmotic control agents. At concentrations
of up to 100 mosm, neither agent decreased cell numbers.
However, at 150 mosm, both sorbitol and sodium chloride
caused a small but signi¢cant decrease in cell numbers (by
5.0% and 5.2%, respectively; P6 0.05) (Fig. 1B).
Fig. 1. PEG, but not osmotically equivalent doses of sorbitol or so-
dium chloride, dramatically decreased HT-29 cell viability as as-
sessed by MTT assay. A: PEG caused a dose-dependent inhibition
in cell numbers. All PEG-treated data points were signi¢cantly low-
er (P6 0.05) than the corresponding vehicle-treated group. When
compared to day 1, PEG concentrations v 45 mM and v 30 mM
gave statistically signi¢cant cell number reduction at days 2 and 3,
respectively. B: Treatment for 3 days with osmotic controls, sorbitol
and sodium chloride. P6 0.05 versus vehicle.
Fig. 2. PEG did not alter expression of PCNA. Representative
Western blot assay of two observations of HT-29 treated with ve-
hicle or PEG 50 mM for 3 days. Densitometric analysis of 10 sepa-
rate experiments did not reveal any signi¢cant di¡erences in PCNA
expression in the vehicle- versus PEG-treated cells.
Fig. 3.
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To better understand the mechanism by which PEG de-
creased cell numbers, we assessed both cell proliferation and
apoptosis. Cell proliferation was assessed through PCNA ex-
pression, a well-validated marker of proliferative status [13].
Treatment with 50 mM PEG for 5 days had no signi¢cant
e¡ect on PCNA expression (Fig. 2). Moreover, £ow cytomet-
ric analysis did not demonstrate any alterations in cell cycle
distribution (data not shown). Next, we focused on apoptosis
using two distinct methodologies. Our primary method was
via assessment of reactivity to the M30 antibody, a well-vali-
dated early marker of apoptosis in colon carcinogenesis [14].
PEG resulted in a dose-dependent increase in apoptosis in
HT-29 cells (Fig. 3A). Immunocytochemical detection of
M30 yielded comparable results to FACS analysis (data not
shown). We con¢rmed the apoptosis fraction by analyzing the
subdiploid fraction detected through £ow cytometry (Fig.
3A). The similarity of results obtained from M30 and DNA
degradation-based methods of apoptosis quantitation is in
agreement with our previous work in HT-29 cells [10] and a
recent report in human colon carcinogenesis [14]. To ascertain
that these e¡ects were not cell line speci¢c, we demonstrated
similar although somewhat less dramatic results in the other
human adenocarcinoma cell line, CaCo-2 (Fig. 3B).
Finally, in order to investigate the potential mechanisms
involved in PEG-mediated apoptosis, we evaluated the expres-
sion of the pro-apoptotic protein, Par-4, which has previously
been implicated in NSAID-mediated apoptosis in human co-
lon cancer cell lines [8]. Par-4 was faintly detectable in the
vehicle-treated cells, but there was a striking 17-fold induction
of Par-4 expression after treatment with 50 mM PEG (Fig. 4).
4. Discussion
Some recent reports, utilizing the azoxymethane (AOM)
rodent model, have demonstrated a dramatic inhibition of
colon carcinogenesis by PEG [2^6]. This established model
recapitulates many of the genetic, cellular and pathological
events in human colorectal cancer [15]. PEG inhibited
AOM-induced aberrant crypt foci, a well-validated intermedi-
ate biomarker of colon cancer, by 80%, and suppressed AOM-
induced colon tumors by 95%. Importantly, the doses of PEG
used did not induce signi¢cant alterations in bowel habits or
other adverse events [2,3]. In contrast to these reports, Nai-
gamwalla and colleagues failed to demonstrate a protective
e¡ect of PEG in a genetic model of intestinal tumorigenesis
[6].
Our report is the ¢rst to demonstrate a biologically plau-
sible mechanism for PEG, thus, underscoring PEG’s role as a
chemopreventive agent against colon cancer. We demon-
strated, in vitro, that PEG reduced cell number in a time-
and dose-dependent manner. While PEG did not inhibit cel-
lular proliferation, it did result in a marked, concentration-
dependent induction in apoptosis. Inhibition of apoptosis is a
critical early event in neoplasia, allowing the otherwise short-
lived colonocyte to acquire the requisite mutations in tumor
suppressor genes and proto-oncogenes [16]. Moreover, induc-
tion of apoptosis has been a central theme in a variety of
chemopreventive agents against colon cancer such as NSAIDs
[1]. The molecular mechanisms behind the induction of apo-
ptosis are still not completely understood; however, an alter-
ation in the balance between pro- and anti-apoptotic proteins
appears to be of importance [17]. Emerging data, from a va-
riety of tissue types, suggest that Par-4, a zinc-¢nger-contain-
ing transcription factor, may be important in the control of
apoptosis [18]. Indeed, a recent study using a human colon
cancer cell line demonstrated a marked induction in Par-4 by
NSAIDs [8]. Par-4 appears to be important in the control of
apoptosis in cells transformed by Ras [19], a proto-oncogene
frequently activated in colon carcinogenesis [16]. Par-4 may
act at least partly through inhibition of NF-UB and Bcl-2 [20].
Additionally, Par-4 interacts with atypical protein kinase C
isoforms [21], such as PKC j, which we have previously
shown to be an important mechanism in the chemoprevention
of colon cancer by NSAIDs [22]. Our data demonstrated that
PEG induced a 17-fold induction in Par-4 expression, a ¢nd-
ing suggesting a potential mechanism for PEG-mediated apo-
ptosis and chemoprevention. However, because we did not
assess other putative modulators of NSAID-induced apopto-
sis, such as 15-lipoxygenase 1 [23] or BAX/BCL-XL [24], we
cannot conclude that Par-4 upregulation is the sole mecha-
nism for PEG-induced apoptosis.
There is biological precedence for compounds with struc-
tural similarity to PEG-inducing apoptosis in cell culture.
Treatment of HT-29 and a hepatocellular cancer cell line
Fig. 3. PEG induced apoptosis in colon cancer cell lines in a dose-
dependent fashion. Cells were treated for 3 days with PEG or ve-
hicle. A: Representative assays for apoptosis, all conducted with 50
mM PEG for 3 days. (I) M30 by FACS analysis. The light line rep-
resents control cells while the dark line is the PEG-treated cells.
PEG causes a marked increase in cells recognized by the M30 anti-
body. (II) Flow cytometric analysis of DNA content in vehicle-
treated cells. The arrowheads represent cells with 2N and 4N DNA
content. The subdiploid (apoptotic) fraction is clearly identi¢ed.
(III) Flow cytometric analysis of DNA content in the PEG-treated
group. The arrowhead represents 2N DNA content. There is a
marked increase in the subdiploid fraction with PEG treatment.
B: Dose-dependent induction of apoptosis by M30-FACS analysis
in HT-29 cells and CaCo-2 cells treated for 3 days.
Fig. 4. PEG treatment dramatically induced Par-4. Representative
Western blot assay of two observations of HT-29 treated with ve-
hicle or PEG 50 mM for 3 days. Densitometric analysis of ten sepa-
rate experiments revealed a 17-fold induction in Par-4 expression
with PEG treatment (P6 0.001).
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with Triton X-100 resulted in apoptosis [25,26]. Similar data
have been reported with two other non-ionic detergents,
Tween 20 and NP-40 [27]. Induction of apoptosis with these
agents may be related to caspase 3 activation [27], potentially
through alterations in dimerization or in subcellular distribu-
tion of proteins in the Bcl-2 family [28]. While PEG shares
many chemical similarities with these agents, particularly side-
chain composition, it lacks much of their detergent ability.
Many of these detergent studies do not exclude the possibility
that their osmotic properties alone may lead to apoptosis, as
has been previously demonstrated in cell culture [29]. In our
report, the lack of e¡ect on cell numbers from osmotic con-
trols strongly supports a speci¢c role of PEG. Another poten-
tial confounding factor is PEG-induced cell fusion which has
been described in HT-29 cells, but at very high PEG concen-
trations (27% v/v) [30]. We were unable to detect any evidence
of this either by microscopy or £ow cytometric analysis of
DNA content, again, arguing for a speci¢c e¡ect of PEG.
The moieties on the PEG molecule that determine its apo-
ptotic and, hence, chemopreventive e¡ect have not been ex-
plored; however, the molecular weight of PEG appears to be
important. While a wide range of PEG species (molecular
weights 400^35 000) have been shown to inhibit AOM-in-
duced intermediate biomarkers for colon cancer, the peak
e⁄cacy was at a molecular weight of 8000 [3]. Our study
cannot address this issue due to the limited solubility of
PEG in cell culture. However, the potential for designing
superior PEG derivatives is underscored by the recent dem-
onstration that pluronic F68 block polymer is ¢ve times more
potent than the parent PEG molecule [31].
In conclusion, we demonstrate for the ¢rst time that PEG
induces apoptosis in a time- and dose-dependent fashion in
human cancer cell lines. Our data suggest that induction of
Par-4 may be responsible, at least in part, for this decrease in
cell survival. These observations provide another compelling
line of evidence that reinforces PEG’s potential as a chemo-
preventive agent against colorectal cancer. Further studies are
necessary to completely understand the mechanisms involved.
References
[1] Janne, P.A. and Mayer, R.J. (2000) New Engl. J. Med. 342,
1960^1968.
[2] Corpet, D.E. and Parnaud, G. (1999) Carcinogenesis 20, 915^
918.
[3] Parnaud, G., Tache, S., Pei¡er, G. and Corpet, D.E. (1999) Can-
cer Res. 59, 5143^5147.
[4] Wali, R.K., Skarosi, S., Hart, J., Zhang, Y., Dolan, M.E.,
Moschel, R.C., Nguyen, L., Musta¢, R., Brasitus, T.A. and
Bissonnette, M. (1999) Carcinogenesis 20, 2355^2360.
[5] Corpet, D.E., Parnaud, G., Delverdier, M., Pei¡er, G. and
Tache, S. (2000) Cancer Res. 60, 3160^3164.
[6] Naigamwalla, D., Chia, M.C., Tran, T.T., Medline, A., Hay, K.,
Gallinger, S. and Bruce, W.R. (2000) Cancer Res. 60, 6856^6858.
[7] DiPalma, J.A., DeRidder, P.H., Orlando, R.C., Kolts, B.E. and
Cleveland, M.B. (2000) Am. J. Gastroenterol. 95, 446^450.
[8] Zhang, Z. and DuBois, R.N. (2000) Gastroenterology 118, 1012^
1017.
[9] Rahman, M.A., Dhar, D.K., Masunaga, R., Yamanoi, A., Koh-
no, H. and Nagasue, N. (2000) Cancer Res. 60, 2085^2089.
[10] Roy, H.K., Karolski, W.J., Ratashak, A. and Smyrk, T.C. (2001)
Br. J. Cancer, in press.
[11] Vermes, I., Haanen, C. and Reutelingsperger, C. (2000) J. Im-
munol. Methods. 243, 167^190.
[12] Roy, H.K., Karolski, W.J. and Ratashak, A. (2001) Int. J. Can-
cer, in press.
[13] Lohr, F., Wenz, F., Haas, S. and Flentje, M. (1995) Cell Prolif.
28, 93^104.
[14] Carr, N.J. (2000) Arch. Pathol. Lab. Med. 124, 1768^1772.
[15] Banerjee, A. and Quirke, P. (1998) Dis. Colon Rectum 41, 490^
505.
[16] Chung, D.C. (2000) Gastroenterology 119, 854^865.
[17] Hengartner, M.O. (2000) Nature 407, 770^776.
[18] Sells, S.F., Han, S.S., Muthukkumar, S., Maddiwar, N., John-
stone, R., Boghaert, E., Gillis, D., Liu, G., Nair, P., Monnig, S.,
Collini, P., Mattson, M.P., Sukhatme, V.P., Zimmer, S.G., Wood
Jr., D.P., McRoberts, J.W., Shi, Y. and Rangnekar, V.M. (1997)
Mol. Cell. Biol. 17, 3823^3832.
[19] Barradas, M., Monjas, A., Diaz-Meco, M.T., Serrano, M. and
Moscat, J. (1999) EMBO J. 18, 6362^6369.
[20] Camandola, S. and Mattson, M.P. (2000) J. Neurosci. Res. 61,
134^139.
[21] Diaz-Meco, M.T., Municio, M.M., Frutos, S., Sanchez, P.,
Lozano, J., Sanz, L. and Moscat, J. (1996) Cell 86, 777^786.
[22] Roy, H.K., Bissonnette, M., Frawley, B.P., Wali, R.K., Niedzie-
la, S.M., Earnest, D. and Brasitus, T.A. (1995) FEBS Lett. 366,
143^145.
[23] Shureiqi, I., Chen, D., Lee, J.J., Yang, P., Newman, R.A., Bren-
ner, D.E., Lotan, R., Fischer, S.M. and Lippman, S.M. (2000)
J. Natl. Cancer Inst. 92, 1136^1142.
[24] Zhang, L., Yu, J., Park, B.H., Kinzler, K.W. and Vogelstein, B.
(2000) Science 290, 989^992.
[25] Borner, M.M., Schneider, E., Pirnia, F., Sartor, O., Trepel, J.B.
and Myers, C.E. (1994) FEBS Lett. 353, 129^132.
[26] Ahn, J.M., Kim, S.J., Kim, H., Park, C., Kim, W.H. and Park,
J.H. (1997) Yonsei Med. J. 38, 52^59.
[27] Strupp, W., Weidinger, G., Scheller, C., Ehret, R., Ohnimus, H.,
Girschick, H., Tas, P., Flory, E., Heinkelein, M. and Jassoy, C.
(2000) J. Membr. Biol. 175, 181^189.
[28] Hsu, Y.T. and Youle, R.J. (1997) J. Biol. Chem. 272, 13829^
13834.
[29] Mockridge, J.W., Benton, E.C., Andreeva, L.V., Latchman, D.S.,
Marber, M.S. and Heads, R.J. (2000) Biochem. Biophys. Res.
Commun. 273, 322^327.
[30] Laboisse, C.L., Maoret, J.J., Triadou, N. and Augeron, C. (1988)
Cancer Res. 48, 2498^2504.
[31] Parnaud, G., Tache, S., Pei¡er, G. and Corpet, D.E. (2001) Br. J.
Cancer 84, 90^93.
FEBS 24847 4-5-01
H.K. Roy et al./FEBS Letters 496 (2001) 143^146146
